A Phase 3 interventional study of olanzapine and lithium in Manic or Mixed Episode Associated With Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 11 sites in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
This study's enrollment of 139 is above the median of 89 across 139 interventional studies indexed under Mania.
Browse Mania studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Olanzapine extension for Study BMAC patients who completed Visit 8. Patients received olanzapine 5-20 mg for 18 weeks.
Drug: olanzapine
Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5. Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks. Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks.
Drug: olanzapine · Drug: lithium · Drug: valproate · Drug: carbamazepine
oral, daily
Also known as: LY170053, Zyprexa
Dose adjusted according to local package insert
Dose adjusted according to local package insert
Dose adjusted according to local package insert
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
Time frame: baseline through 18 weeks
Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only
Defined by a 50% or more reduction in YMRS total score from baseline in Study BMAC to endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
Time frame: baseline through 18 weeks
Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only
Remission of Mania was defined as a YMRS total score of less than or equal to 12 at endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
Time frame: baseline through 18 weeks
Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only
Patients achieved remission in Study BMAC (defined as YMRS total score \<=12 and HAMD-17 total score \<=7) and obtained YMRS total score of \>=15 at any time during Study BMEX. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
Time frame: baseline through 18 weeks
Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: baseline through 18 weeks
Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) Overall, Visit Data
Measures severity of the patient's overall severity of bipolar symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).
Time frame: baseline, Weeks 1, 2, 4, 6, 10, 14, 18
Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)
Incidence of depressive symptoms was defined as a score of equal to or more than 13 points on the HAMD-17. The 17-item HAMD measures depression severity. Each item was evaluated and scored a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
Time frame: baseline through 18 weeks
Number of Participants With Relapse of Depressive Symptoms
Assessed were participants meeting remission criteria for bipolar disorder in Study BMAC and have a HAMD-17 total score greater than or equal to 13 at any time. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
Time frame: baseline through 18 weeks
Number of Participants Who Experienced Remission of Bipolar Disorder
Participants who had equal to or less than 12 points in YMRS total score and equal to or less than 7 points in HAMD-17 total score at 18 weeks. YMRS: 11-item scale, measures the severity of manic episodes. 4 items are rated from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total: 0 to 60. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale or a 5-point scale. HAMD-17 total score: 0 (normal) to 52 (severe).
Time frame: Week 18
Positive and Negative Syndrome Scale Positive Scores - Visit Data
Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For the analysis, the score was converted to 0 to 6 for each item range; hence, the total score ranges from 0 to 42.
Time frame: baseline, Weeks 1, 2, 4, 6, 10, 14, 18
Number of Participants Who Switched to Syndromic Depression
As defined as a shift from a Manic Episode at baseline to a Major Depressive Episode, at any post baseline visit, based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.
Time frame: baseline through 18 weeks
Maximum Change From Baseline to Endpoint on the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) - Total Score
A scale used to assess the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by the total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by the points given to the corresponding items.
Time frame: baseline through 18 weeks
Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). Parkinsonism is assessed by the total points of items 1 to 5 (total score of 0 to 20). Treatment-emergent parkinsonism was defined as a score of equal or greater than 3 on 1 item, equal or greater than 2 on 2 items, or an increase of equal or greater than 3 from baseline on the parkinsonism total.
Time frame: baseline through 18 weeks
Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent akathisia was defined as a score of equal or more than 2 or an increase of equal or more than 2 points from baseline on the akathisia item (total score possible 0 to 4 points).
Time frame: baseline through 18 weeks
Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dystonia was defined as a score equal or more than 2 or an increase of equal or more than 2 points from baseline on the dystonia item (total score possible 0 to 4 points).
Time frame: baseline through 18 weeks
Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dyskenisia was defined as a score of equal or more than 2 or an increase of equal to or more than 2 points from baseline on the dyskenisia item (total score possible 0 to 4 points).
Time frame: baseline through 18 weeks
Number of Participants With Potentially Clinically Significant Changes in Laboratory Analytes
Triglycerides: high limit equal to or more than 500 milligram/deciliter (mg/dL); Glucose (non-fasting): low limit 2.4975 mmol/liter (L); high limit 13.875 mmol/L; Glucose (fasting): low limit 2.4975 mmol/L; high limit 6.993 mmol/L.
Time frame: baseline through 18 weeks
Number of Participants With Potentially Clinically Significant Changes in Vital Signs and Weight
Low systolic blood pressure (SBP): \<=90 millimeter mercury (mmHg) and decrease of \>=20 mmHg; High SBP: \>=180 mmHg and increase of \>=20 mmHg; Low diastolic blood pressure (DBP): \<=50 mmHg and decrease of \>=15 mmHg; High DBP: \>=105 mmHg and increase of \>=15 mmHg; Low pulse: \<50 beats per minute (bpm) and decrease of \>=15 bpm; High pulse: \>120 bpm and an increase of \>=15 bpm; Low weight: decrease of \>=7%; High weight: increase of \>=7%;
Time frame: baseline through 18 weeks
Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)
High QTcF: more than or equal to 450 milliseconds (msec) for males; more than or equal to 470 milliseconds (msec) for females
Time frame: baseline through 18 weeks
Number of Participants With Treatment-emergent Abnormal, High, or Low Laboratory Values
High density lipoprotein: males low 40 milligram/deciliter (mg/dL), high 80 mg/dL; females low 40 mg/dL, high 90 mg/dL. Low density lipoprotein (LDL): males and females low 70 mg/dL, high 139 mg/dL. Hemoglobin A1C (HBA1C): males and females low 4.3%, high 5.8%.
Time frame: baseline through 18 weeks
| Milestone | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Started | 100 | 39 |
| Completed | 58 | 11 |
| Not completed | 42 | 28 |
| Withdrew: Adverse event | 8 | 6 |
| Withdrew: Lack of efficacy | 1 | 4 |
| Withdrew: Entry criteria not met | 1 | 0 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 10 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 19 | 11 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
| units on a scale | Olanzapine Monotherapy |
|---|---|
| Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only | -3.0 ± 5.6 |
Defined by a 50% or more reduction in YMRS total score from baseline in Study BMAC to endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
| participants | Olanzapine Monotherapy |
|---|---|
| Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only | 97 |
Remission of Mania was defined as a YMRS total score of less than or equal to 12 at endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
| participants | Olanzapine Monotherapy |
|---|---|
| Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only | 93 |
Patients achieved remission in Study BMAC (defined as YMRS total score \<=12 and HAMD-17 total score \<=7) and obtained YMRS total score of \>=15 at any time during Study BMEX. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.
| participants | Olanzapine Monotherapy |
|---|---|
| Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only | 3 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine + Mood Stabilizer |
|---|---|
| Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only | -19.8 ± 17.8 |
Measures severity of the patient's overall severity of bipolar symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).
| units on a scale | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| baseline | 1.9 ± 1.0 | 4.7 ± 0.8 |
| 1 week | 1.8 ± 1.0 | 4.1 ± 1.2 |
| 2 weeks | 1.8 ± 1.0 | 3.7 ± 1.3 |
| 4 weeks | 1.7 ± 1.0 | 3.5 ± 1.6 |
| 6 weeks | 1.7 ± 1.1 | 3.4 ± 1.7 |
| 10 weeks | 1.7 ± 1.1 | 3.0 ± 1.8 |
| 14 weeks | 1.8 ± 1.2 | 3.0 ± 1.9 |
| 18 weeks endpoint | 1.7 ± 1.2 | 2.9 ± 2.0 |
Incidence of depressive symptoms was defined as a score of equal to or more than 13 points on the HAMD-17. The 17-item HAMD measures depression severity. Each item was evaluated and scored a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17) | 4 | 1 |
Assessed were participants meeting remission criteria for bipolar disorder in Study BMAC and have a HAMD-17 total score greater than or equal to 13 at any time. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
| participants | Olanzapine Monotherapy |
|---|---|
| Number of Participants With Relapse of Depressive Symptoms | 4 |
Participants who had equal to or less than 12 points in YMRS total score and equal to or less than 7 points in HAMD-17 total score at 18 weeks. YMRS: 11-item scale, measures the severity of manic episodes. 4 items are rated from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total: 0 to 60. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale or a 5-point scale. HAMD-17 total score: 0 (normal) to 52 (severe).
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants Who Experienced Remission of Bipolar Disorder | 54 | 12 |
Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For the analysis, the score was converted to 0 to 6 for each item range; hence, the total score ranges from 0 to 42.
| units on a scale | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| baseline | 7.7 ± 1.8 | 12.5 ± 5.7 |
| 1 week | 7.5 ± 1.6 | 10.5 ± 4.1 |
| 2 weeks | 7.5 ± 1.4 | 10.1 ± 3.9 |
| 4 weeks | 7.4 ± 1.4 | 10.1 ± 5.4 |
| 6 weeks | 7.3 ± 1.2 | 10.1 ± 5.4 |
| 10 weeks | 7.4 ± 1.7 | 9.9 ± 5.4 |
| 14 weeks | 7.4 ± 1.7 | 9.9 ± 5.4 |
| 18 week endpoint | 7.4 ± 1.7 | 9.9 ± 5.4 |
As defined as a shift from a Manic Episode at baseline to a Major Depressive Episode, at any post baseline visit, based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants Who Switched to Syndromic Depression | 8 | 4 |
A scale used to assess the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by the total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by the points given to the corresponding items.
| units on a scale | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Baseline | 0.35 ± 1.01 | 0.18 ± 0.60 |
| Maximum Change from baseline to endpoint | 0.05 ± 1.21 | 0.64 ± 1.51 |
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). Parkinsonism is assessed by the total points of items 1 to 5 (total score of 0 to 20). Treatment-emergent parkinsonism was defined as a score of equal or greater than 3 on 1 item, equal or greater than 2 on 2 items, or an increase of equal or greater than 3 from baseline on the parkinsonism total.
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores | 1 | 3 |
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent akathisia was defined as a score of equal or more than 2 or an increase of equal or more than 2 points from baseline on the akathisia item (total score possible 0 to 4 points).
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores | 3 | 2 |
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dystonia was defined as a score equal or more than 2 or an increase of equal or more than 2 points from baseline on the dystonia item (total score possible 0 to 4 points).
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores | 0 | 1 |
DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dyskenisia was defined as a score of equal or more than 2 or an increase of equal to or more than 2 points from baseline on the dyskenisia item (total score possible 0 to 4 points).
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores | 0 | 0 |
Triglycerides: high limit equal to or more than 500 milligram/deciliter (mg/dL); Glucose (non-fasting): low limit 2.4975 mmol/liter (L); high limit 13.875 mmol/L; Glucose (fasting): low limit 2.4975 mmol/L; high limit 6.993 mmol/L.
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| High triglycerides; n=100, n=38 | 5 | 2 |
| Low glucose (non-fasting); n=64, n=28 | 0 | 0 |
| High glucose (non-fasting); n=64, n=28 | 0 | 0 |
| Low glucose (fasting); n=40, n=6 | 0 | 0 |
| High glucose (fasting); n=40, n=6 | 3 | 0 |
Low systolic blood pressure (SBP): \<=90 millimeter mercury (mmHg) and decrease of \>=20 mmHg; High SBP: \>=180 mmHg and increase of \>=20 mmHg; Low diastolic blood pressure (DBP): \<=50 mmHg and decrease of \>=15 mmHg; High DBP: \>=105 mmHg and increase of \>=15 mmHg; Low pulse: \<50 beats per minute (bpm) and decrease of \>=15 bpm; High pulse: \>120 bpm and an increase of \>=15 bpm; Low weight: decrease of \>=7%; High weight: increase of \>=7%;
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Low systolic blood pressure | 6 | 2 |
| High systolic blood pressure | 0 | 0 |
| Low diastolic blood pressure | 4 | 1 |
| High diastolic blood pressure | 1 | 0 |
| Low weight | 3 | 1 |
| High weight | 17 | 10 |
| Low pulse | 0 | 0 |
| High pulse | 0 | 0 |
High QTcF: more than or equal to 450 milliseconds (msec) for males; more than or equal to 470 milliseconds (msec) for females
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF) | 0 | 0 |
High density lipoprotein: males low 40 milligram/deciliter (mg/dL), high 80 mg/dL; females low 40 mg/dL, high 90 mg/dL. Low density lipoprotein (LDL): males and females low 70 mg/dL, high 139 mg/dL. Hemoglobin A1C (HBA1C): males and females low 4.3%, high 5.8%.
| participants | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Low high density lipoprotein (HDL); n=93, n=36 | 10 | 3 |
| High high density lipoprotein (HDL); n=95, n=37 | 5 | 1 |
| Low low density lipoprotein (LDL); n=97; n=37 | 1 | 1 |
| High low density lipoprotein (LDL); n=71, n=31 | 24 | 11 |
| Low hemoglobin A1C (HBA1C); n=100, n=39 | 1 | 1 |
| High hemoglobin A1C (HBA1C); n=97, n=38 | 2 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine Monotherapy | — | 1/100 (1%) | 59/100 (59%) |
| Olanzapine + Mood Stabilizer | — | 0/39 (0%) | 31/39 (79.5%) |
| Event | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 1/100 | 0/39 |
| Event | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer |
|---|---|---|
| SomnolenceNervous system disorders | 15/100 | 7/39 |
| NasopharyngitisInfections and infestations | 17/100 | 6/39 |
| Blood triglycerides increasedInvestigations | 5/100 | 6/39 |
| Weight increasedInvestigations | 9/100 | 5/39 |
| ConstipationGastrointestinal disorders | 3/100 | 3/39 |
| Alanine aminotransferase increasedInvestigations | 2/100 | 3/39 |
| Blood cholesterol increasedInvestigations | 3/100 | 3/39 |
| Depressive symptomPsychiatric disorders | 7/100 | 2/39 |
| ThirstGeneral disorders | 5/100 | 2/39 |
| ContusionInjury, poisoning and procedural complications | 2/100 | 2/39 |
| Age Continuous(years) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Mean | 41.8 ± 11.7 | 43.2 ± 11.1 | 42.2 ± 11.6 |
| Sex: Female, Male(Participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Female | 59 | 21 | 80 |
| Male | 41 | 18 | 59 |
| Race/Ethnicity, Customized(participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Japanese | 100 | 39 | 139 |
| Region of Enrollment(participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Japan | 100 | 39 | 139 |
| Current Episode - Mixed or Manic(participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Manic | 88 | 39 | 127 |
| Mixed | 12 | 0 | 12 |
| Current Episode - Psychotic or Nonpsychotic(participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Psychotic | 13 | 9 | 22 |
| Nonpsychotic | 87 | 30 | 117 |
| Rapid Cyclers(participants) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Rapid Cyclers | 7 | 3 | 10 |
| Non-Rapid Cyclers | 93 | 36 | 129 |
| Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) overall(units on a scale) | Olanzapine Monotherapy | Olanzapine + Mood Stabilizer | Total |
|---|---|---|---|
| Mean | 1.9 ± 1.0 | 4.7 ± 0.8 | 2.7 ± 1.6 |
4 further baseline measures are reported on the registry.
The record gives a start of Nov 2005, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine